Loading clinical trials...
Loading clinical trials...
Phase II Study of HRS-4642 in Combination With Nimotuzumab and Chemotherapy for Subjects With Borderline Resectable Pancreatic Cancer With KRAS G12D Mutation
Conditions
Interventions
HRS-4642+AG+Nimotuzumab
Locations
2
China
First Affiliated Hospital of Zhejiang University Schlool of Medicine
Hangzhou, Zhejiang, China
the First Affiliated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China
Start Date
February 15, 2026
Primary Completion Date
May 15, 2027
Completion Date
November 15, 2028
Last Updated
February 13, 2026
NCT05825066
NCT05688215
NCT05356039
NCT04481204
NCT04669197
NCT05546411
Lead Sponsor
Zhejiang University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions